Tag
The INTERCEPT study demonstrates that longitudinal ctDNA testing effectively detects minimal residual disease post-curative treatment in colorectal cancer, enhancing recurrence prediction and refining risk stratification to guide future int
Circulating tumor cells (CTCs) enhance the IMS-IMWG 2025 genomic staging by identifying a disseminated high-risk phenotype in newly diagnosed multiple myeloma, improving prognostic stratification and enabling minimally invasive disease moni
In the GHSG HD21 trial, a validated ctDNA assay showed that MRD positivity after two treatment cycles strongly predicted inferior progression-free survival and improved early risk stratification, especially when combined with interim PET.
Circulating tumor cells (CTCs) serve as an independent prognostic biomarker in transplant-eligible newly diagnosed multiple myeloma patients treated with daratumumab-based quadruplet therapy, predicting progression-free survival and minimal
Detection of circulating tumor DNA (ctDNA) provides a highly prognostic method for assessing remission in large B-cell lymphoma, outperforming conventional imaging and promising improved patient outcomes.
Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.
